Neurogene Inc. 8K

Neurogene Inc. reported strong, durable Phase 1/2 results and completion of dosing in its Embolden registrational trial for NGN‑401 in Rett syndrome, with topline data expected in 2H 2027 to support a planned BLA and associated commercial preparations.

Neurogene Inc. furnished an investor presentation updating progress on NGN-401, its gene therapy candidate for Rett syndrome, highlighting long‑term Phase 1/2 data that show durable, multidomain developmental gains in all 10 treated participants and reporting that dosing has been completed in the 25‑patient Embolden registrational trial, which is expected to deliver topline data in the second half of 2027 to support a potential BLA submission. The company reported that NGN-401 at a 1E15 vg intracerebroventricular dose has generally been well tolerated with no treatment-related serious adverse events or dose-limiting toxicities in either the Phase 1/2 or Embolden trials, and emphasized that 80% of Phase 1/2 participants met the Embolden composite responder definition at 12 months and that developmental milestones continued to accumulate up to 30 months without loss. Neurogene also indicated it is advancing commercial readiness, including adding a Chief Commercial Officer, initiating PPQ manufacturing campaigns in mid‑2026, and believes its cash resources are expected to fund operations through the Embolden data readout, BLA submission, and key pre‑launch activities, positioning NGN‑401 as a potential first- or best-in-class disease-modifying therapy for Rett syndrome across pediatric and adult populations.

Filing Facts

CIK

1404644

Ticker

NGNE

Form

8K

Source Type

sec

Accession

0001404644-26-000046

Alert Tier

6